Item 2.01. Completion of Acquisition or Disposition of Assets.

On January 26, 2021, BridgeBio Pharma, Inc. ("BridgeBio") completed the acquisition of all of the shares of common stock (the "Eidos Common Stock") of Eidos Therapeutics, Inc. ("Eidos") that it did not already own, pursuant to the Agreement and Plan of Merger, dated as of October 5, 2020 (the "Merger Agreement"), by and among BridgeBio Pharma, Inc. ("BridgeBio"), Eidos, Globe Merger Sub I, Inc. ("Merger Sub I") and Globe Merger Sub II, Inc. ("Merger Sub II"). Under the Merger Agreement, Merger Sub I merged with and into Eidos (the "Initial Merger"), with Eidos surviving the Initial Merger, and thereafter Eidos merged with and into Merger Sub II (the "Subsequent Merger" and, together with the Initial Merger, the "Mergers"), with Merger Sub II surviving the Subsequent Merger as an indirect and wholly owned subsidiary of BridgeBio under the name "Eidos Therapeutics, Inc."

At the effective time of the Initial Merger (the "Effective Time"), each share of common stock, par value $0.001 per share, of Eidos ("Eidos Common Stock") issued and outstanding immediately prior to the Effective Time (other than shares of Eidos Common Stock (i) owned by Eidos as treasury stock, (ii) owned by Eidos, BridgeBio, Merger Sub, Merger Sub II or any other direct or indirect wholly owned subsidiary of BridgeBio and, in each case, not held on behalf of third parties and (iii) shares of Eidos Common Stock that are subject to Eidos Restricted Share Awards (as defined below)) was converted into the right to receive, at the election of each stockholder of Eidos, (A) 1.85 shares of BridgeBio's common stock ("BridgeBio Common Stock"), par value $0.001 per share (the "Stock Consideration"), or (B) $73.26 in cash (the "Cash Consideration"). From and after the Effective Time, all shares of Eidos Common Stock were cancelled and now represent only the right to receive, as applicable, the Stock Consideration or the Cash Consideration.

Immediately prior to the Effective Time, (i) each option to purchase Eidos Common Stock (an "Eidos Option") was converted into an option, on the same terms and conditions applicable to such Eidos Option immediately prior to the Effective Time, to purchase a specified number of shares of BridgeBio Common Stock, calculated pursuant to the terms of the Merger Agreement, and (ii) each outstanding award of shares of Eidos Common Stock that is subject to forfeiture conditions (subject to certain exceptions) (each, an "Eidos Restricted Share Award") was converted into an award covering a number of whole restricted shares of BridgeBio Common Stock, calculated pursuant to the terms of the Merger Agreement, with any fractional shares being paid out to the holder of such Eidos Restricted Share Award in cash.

The issuance of BridgeBio Common Stock in connection with the Mergers was registered under the Securities Act of 1933, as amended, pursuant to BridgeBio's Registration Statement on Form S-4, which was filed with the U.S. Securities and Exchange Commission (the "SEC") on November 6, 2020 (as amended, the "Form S-4"). The Form S-4 was declared effective on December 15, 2020. The Form S-4 and the joint proxy statement/prospectus included therewith contain additional information about the Mergers.

Upon the closing of the Mergers, the shares of Eidos Common Stock that were previously listed on the Nasdaq ceased trading on, and were delisted from, the Nasdaq. The shares of Eidos Common Stock will subsequently be deregistered under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

The foregoing description of the Mergers and the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which is filed as Exhibit 2.1 hereto, and incorporated into this Current Report on Form 8-K by reference in its entirety.

Item 7.01. Regulation FD Disclosure.

On January 26, 2021, BridgeBio released a press release announcing the completion of the Mergers, which is filed herewith as Exhibit 99.1 and incorporated by reference herein.

The information disclosed under this Item 7.01, including Exhibit 99.1 shall be considered "furnished" but not "filed" for purposes of the Exchange Act.


--------------------------------------------------------------------------------

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.



Exhibit
  No.                               Description of Exhibit

 2.1          Agreement and Plan of Merger, dated as of October  5, 2020, by and
            among BridgeBio Pharma, Inc., Eidos Therapeutic, Inc., Globe Merger
            Sub I, Inc. and Globe Merger Sub II, Inc. (incorporated by reference
            to Exhibit 2.1 to BridgeBio's Current Report on Form 8-K filed with
            the SEC on October 6, 2020)

99.1          Press Release, dated January 26, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses